BGI's $250 Million Shenzhen IPO Scheduled for July

22:05 EDT 23 Jun 2017 | ChinaBio Today

BGI, a Shenzhen genomics company, is edging closer to an IPO. The company now expects to raise $250 million on Shenzhen's Chi-Next Exchange sometime in July, following all-but-final approvals from China's Securities Regulatory Commission. Known as a world leader in basic science sequencing, BGI now generates 55% of its income from clinical genomic tests, especially its NIFTY prenatal test for hereditary illnesses such as Down's syndrome. The business is very profitable: BGI's IPO prospectus puts gross profit margin for reproductive services at 76%. More details....

Share this with colleagues:  

Original Article: BGI's $250 Million Shenzhen IPO Scheduled for July


More From BioPortfolio on "BGI's $250 Million Shenzhen IPO Scheduled for July"

Quick Search


Relevant Topic

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...